Cravens & CO Advisors, LLC Bristol Myers Squibb CO Transaction History
Cravens & CO Advisors, LLC
- $135 Billion
- Q2 2024
A detailed history of Cravens & CO Advisors, LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Cravens & CO Advisors, LLC holds 5,843 shares of BMY stock, worth $287,066. This represents 0.18% of its overall portfolio holdings.
Number of Shares
5,843Holding current value
$287,066% of portfolio
0.18%Shares
1 transactions
Others Institutions Holding BMY
# of Institutions
2,400Shares Held
1.5BCall Options Held
29.7MPut Options Held
32.2M-
Vanguard Group Inc Valley Forge, PA187MShares$9.17 Billion0.15% of portfolio
-
Black Rock Inc. New York, NY159MShares$7.79 Billion0.15% of portfolio
-
State Street Corp Boston, MA91.4MShares$4.49 Billion0.17% of portfolio
-
Jpmorgan Chase & CO New York, NY74.6MShares$3.67 Billion0.27% of portfolio
-
Charles Schwab Investment Management Inc San Francisco, CA59.1MShares$2.9 Billion0.47% of portfolio
About BRISTOL MYERS SQUIBB CO
- Ticker BMY
- Exchange NYSE
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 2,126,160,000
- Market Cap $104B
- Description
- Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...